ArticleMolecular pharmaceutics2025
Machine Learning Analysis of Cytotoxicity Determinants in Nanoparticle-Based Rheumatoid Arthritis Therapies.
Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence in rheumatoid arthritis: current applications and future perspectives.Frontiers in medicine · 2026Pooled it
- Engineering smart polymeric lipid nanoparticles for breast cancer: AI-guided formulation design, biological barriers, and translational constraints.Journal of nanobiotechnology · 2026Review
- Advances in nanotechnology for the diagnosis and management of autoimmune diseases.Asian journal of pharmaceutical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticle-based therapies have gained attention in recent years as promising treatments for rheumatoid arthritis (RA), due to the potential offered for targeted delivery, controlled drug release, and improved biocompatibility. A deep understanding of the factors that drive cytotoxicity is crucial for safer and more effective nanomedicine formulations. To systematically analyze the determinants of cytotoxicity reported in the literature, we constructed a data set comprising 2,060 instances from 56 publications. Each instance was described by 23 features covering nanoparticle characteristics, cellular environment factors, and assay conditions potentially associated with cytotoxicity. Machine learning (ML) approaches were incorporated to gain deeper insight into key cytotoxicity drivers. We combined Boruta for feature selection, Random Forest (RF) for cytotoxicity prediction and feature importance evaluation, and Association Rule Mining (ARM) for rule-based, hidden pattern discovery. Boruta feature selection results identified the drug and nanoparticle concentration, core-shell material, and cell type as major determinants of cytotoxicity. The RF model demonstrated a strong predictive performance, further confirming the significance of these features. Moreover, ARM revealed high-confidence association rules linking specific conditions, such as high drug concentrations and poly(aspartic acid)-based systems, to cytotoxic outcomes. This structured machine learning framework provides a foundation for optimizing nanoparticle formulations that balance therapeutic efficacy with cellular safety in RA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.